Radioligand Therapy (RLT) in 2025: The New Billion-Dollar Frontier in Oncology
The radioligand therapy market is growing rapidly, driven by rising cancer cases, advances in nuclear medicine, and targeted therapies using radioisotopes like Lutetium-177 and Actinium-225.
January 29, 2026